Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115061) titled 'Efficacy and Safety of Atezolizumab Combined with Bevacizumab and Local Therapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study' on Dec. 22, 2025.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Zhongda Hospital, Affiliated to Southeast University
Condition:
Hepatocellular Carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-22
Target Sample Size: Atezolizumab + Bevacizumab Combined with Locoregional Therapies:1136;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn...